Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
cell therapy
Biotech
Senti slams brakes on CAR-NK program to eke out remaining cash
Senti, seeing the end of its cash runway hove into view, has dropped its liver cancer candidate and narrowed its focus onto two CAR-NK programs.
Nick Paul Taylor
Jan 27, 2023 9:40am
Tessera makes the case for gene writing tech at JPM
Jan 17, 2023 12:56pm
Coya debuts in final moment of 2022 with $15M IPO
Jan 3, 2023 11:05am
Gilead lands a new cell therapy for Kite in $225M Arcellx deal
Dec 9, 2022 10:00am
BioCardia off-the-shelf cell therapy to enter phase 1/2 study
Dec 6, 2022 11:19am
Mesoblast sees cell therapy survival data as key to resubmission
Nov 23, 2022 9:30am
